Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Through the Sehat Sathi App business can access unsecured business loans at low interest
It strengthens its presence to over 250 stores
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Subscribe To Our Newsletter & Stay Updated
